stoxline Quote Chart Rank Option Currency Glossary
  
Lantheus Holdings, Inc. (LNTH)
83.41  3.47 (4.34%)    02-18 16:00
Open: 80.95
High: 84.24
Volume: 1,112,690
  
Pre. Close: 79.94
Low: 80.3475
Market Cap: 5,799(M)
Technical analysis
2025-02-18 4:45:12 PM
Short term     
Mid term     
Targets 6-month :  108.31 1-year :  117.95
Resists First :  92.73 Second :  100.98
Pivot price 87.61
Supports First :  79.38 Second :  66.05
MAs MA(5) :  81.86 MA(20) :  89.7
MA(100) :  95.76 MA(250) :  88.34
MACD MACD :  -3 Signal :  -1.9
%K %D K(14,3) :  13 D(3) :  9
RSI RSI(14): 38.5
52-week High :  126.88 Low :  56.06
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LNTH ] has closed above bottom band by 26.1%. Bollinger Bands are 12.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 84.36 - 84.83 84.83 - 85.27
Low: 79.12 - 79.73 79.73 - 80.29
Close: 82.51 - 83.41 83.41 - 84.23
Company Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Headline News

Tue, 18 Feb 2025
Peregrine Capital Management LLC Trims Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH) - MarketBeat

Mon, 17 Feb 2025
Focus Financial Network Inc. Purchases New Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) - MarketBeat

Sat, 15 Feb 2025
Stanley Laman Group Ltd. Cuts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) - MarketBeat

Thu, 13 Feb 2025
Lacklustre Performance Is Driving Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Low P/E - Simply Wall St

Wed, 12 Feb 2025
Q4 Earnings Alert: Lantheus Set to Unveil Critical 2024 Performance Data - StockTitan

Tue, 04 Feb 2025
Lantheus Holdings, Inc. (LNTH): Among the Best Low Risk High Growth Stocks To Invest In Now - Insider Monkey

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 70 (M)
Shares Float 63 (M)
Held by Insiders 3 (%)
Held by Institutions 110.9 (%)
Shares Short 7,150 (K)
Shares Short P.Month 6,190 (K)
Stock Financials
EPS 6.01
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 16.96
Profit Margin 28.5 %
Operating Margin 35.3 %
Return on Assets (ttm) 17 %
Return on Equity (ttm) 45.5 %
Qtrly Rev. Growth 18.3 %
Gross Profit (p.s.) 13.85
Sales Per Share 21.57
EBITDA (p.s.) 7.88
Qtrly Earnings Growth -4.9 %
Operating Cash Flow 499 (M)
Levered Free Cash Flow 246 (M)
Stock Valuations
PE Ratio 13.85
PEG Ratio 0
Price to Book value 4.91
Price to Sales 3.86
Price to Cash Flow 11.61
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android